LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 128

Search options

  1. Article ; Online: A case of secondary migralepsy in a patient with fibromuscular dysplasia.

    Romozzi, Marina / Rollo, Eleonora / Gnoni, Valentina / Vollono, Catello

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2024  

    Language English
    Publishing date 2024-02-17
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-024-07400-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Primary headaches prevalence, characteristics, and healthcare utilization in Italian medical students.

    Romozzi, Marina / Trigila, Vincenzo / Cuffaro, Giovanni / Calabresi, Paolo / Vollono, Catello

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2024  

    Abstract: Background: Among university students, migraine is notably prevalent and is linked to compromised academic performance and daily functioning. Medical students are a particularly vulnerable category due to the demanding nature of their training, as they ... ...

    Abstract Background: Among university students, migraine is notably prevalent and is linked to compromised academic performance and daily functioning. Medical students are a particularly vulnerable category due to the demanding nature of their training, as they are often exposed to headache trigger factors. We therefore aimed to determine the prevalence, characteristics, and healthcare-seeking practices of primary headaches among Italian medical students.
    Methods: We conducted a cross-sectional study among medical students attending the Università Cattolica del Sacro Cuore in Rome who completed a self-administered questionnaire designed following the International Classification of Headache Disorders-3 criteria. The questionnaire assessed sociodemographic and headache features, healthcare utilization, the use of symptomatic and preventive treatment, and headache trigger factors.
    Results: Five hundred thirty-six students filled out the questionnaire. The lifetime and last-year prevalence of headache in this cohort was 76.7% (n = 411). Among the students surveyed, migraine had a prevalence of 26.9%, probable migraine of 12.9%, and tension-type headache (TTH)/probable TTH of 36.9%. Two hundred and forty-six students (59.8%) reported that their headache worsened after starting university. All students reporting headache had at least one trigger factor. In students fulfilling the criteria for migraine (n = 144), 137 (95.1%) had previously used acute non-prescription treatments, and eight concurrently used a preventive treatment. Thirty-five students fulfilling the criteria for migraine underwent a brain MRI scan (24.3%), 43 performed a neurological evaluation (29.9%), 36 received a diagnosis of migraine (25%), and 20 (13.9%) accessed the emergency room.
    Discussion: Migraine and TTH are common among medical students in Italy despite low healthcare resource utilization. These results support the need to promote public health policies and strategies in order to reduce the disability and burden associated with primary headaches among medical students.
    Language English
    Publishing date 2024-02-12
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-024-07375-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Correction to: Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review.

    Primiano, Guido / Rollo, Eleonora / Romozzi, Marina / Calabresi, Paolo / Servidei, Serenella / Vollono, Catello

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2022  

    Language English
    Publishing date 2022-10-26
    Publishing country Italy
    Document type Published Erratum
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-022-06462-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB.

    Tringali, Giuseppe / Vollono, Catello / Calabresi, Paolo / Navarra, Pierluigi

    The journal of headache and pain

    2020  Volume 21, Issue 1, Page(s) 124

    Abstract: The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. ... ...

    Abstract The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we have measured the circulating levels of CGRP in 7 patients with high-frequency episodic migraine receiving the anti-CGRP receptor mAb erenumab for at least 6 months, to test the hypothesis that long-term blockade of CGRP receptors induces an increase in systemic CGRP levels via a classical up-regulation mechanism.Plasma CGRP levels were measured by a validated radioimmunoassay at baseline, and after 1 and 6 months of treatment with erenumab, 70 mg given sc every 4 weeks.We found (data expressed as the means ± SD): 38.34 ± 30.74 pg CGRP/ml of plasma at baseline, 38.19 ± 29.23 pg/ml after 1 month and 53.89 ± 28.03 pg/ml after 6 months of treatment. Thus, the average increase in plasma CGRP levels after 6 months of treatment was about + 40% compared to both baseline and 1-month treatments; such difference was not statistically significant because of high SD values in all groups.These preliminary findings need to be confirmed in larger, sufficiently powered experiments.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Calcitonin Gene-Related Peptide ; Humans ; Plasma ; Receptors, Calcitonin Gene-Related Peptide
    Chemical Substances Antibodies, Monoclonal, Humanized ; Receptors, Calcitonin Gene-Related Peptide ; erenumab (I5I8VB78VT) ; Calcitonin Gene-Related Peptide (JHB2QIZ69Z)
    Language English
    Publishing date 2020-10-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 2036768-5
    ISSN 1129-2377 ; 1129-2369
    ISSN (online) 1129-2377
    ISSN 1129-2369
    DOI 10.1186/s10194-020-01193-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era.

    Rollo, Eleonora / Romozzi, Marina / Vollono, Catello / Calabresi, Paolo / Geppetti, Pierangelo / Iannone, Luigi F

    Current neuropharmacology

    2022  Volume 21, Issue 8, Page(s) 1767–1785

    Abstract: Migraine and epilepsy are fundamentally distinct disorders that can frequently coexist in the same patient. These two conditions significantly differ in diagnosis and therapy but share some widely- used preventive treatments. Antiseizure medications ( ... ...

    Abstract Migraine and epilepsy are fundamentally distinct disorders that can frequently coexist in the same patient. These two conditions significantly differ in diagnosis and therapy but share some widely- used preventive treatments. Antiseizure medications (ASMs) are the mainstay of therapy for epilepsy, and about thirty different ASMs are available to date. ASMs are widely prescribed for other neurological and non-neurological conditions, including migraine. However, only topiramate and valproic acid/valproate currently have an indication for migraine prophylaxis supported by high-quality evidence. Although without specifically approved indications and with a low level of evidence or recommendation, several other ASMs are used for migraine prophylaxis. Understanding ASM antimigraine mechanisms, including their ability to affect the pro-migraine calcitonin gene-related peptide (CGRP) signaling pathway and other pathways, may be instrumental in identifying the specific targets of their antimigraine efficacy and may increase awareness of the neurobiological differences between epilepsy and migraine. Several new ASMs are under clinical testing or have been approved for epilepsy in recent years, providing novel potential drugs for migraine prevention to enrich the treatment armamentarium and drugs that inhibit the CGRP pathway.
    MeSH term(s) Humans ; Animals ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Seizures/drug therapy ; Drug Approval ; Anticonvulsants/therapeutic use
    Chemical Substances Calcitonin Gene-Related Peptide Receptor Antagonists ; Anticonvulsants
    Language English
    Publishing date 2022-12-28
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 2192352-8
    ISSN 1875-6190 ; 1570-159X
    ISSN (online) 1875-6190
    ISSN 1570-159X
    DOI 10.2174/1570159X21666221228095256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review.

    Primiano, Guido / Rollo, Eleonora / Romozzi, Marina / Calabresi, Paolo / Servidei, Serenella / Vollono, Catello

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2022  Volume 43, Issue 12, Page(s) 6955–6959

    Abstract: Migraine is a common condition in mitochondrial diseases, with a higher prevalence than in the general population. Although several clinical studies support the hypothesis that mitochondrial dysfunction plays a central role in the pathophysiology of ... ...

    Abstract Migraine is a common condition in mitochondrial diseases, with a higher prevalence than in the general population. Although several clinical studies support the hypothesis that mitochondrial dysfunction plays a central role in the pathophysiology of migraine, currently there are few data in the literature regarding the efficacy and safety of drugs for the treatment and prophylaxis for this condition in patients with primary mitochondrial disorders. We report a 37-year-old woman affected by mitochondrial disease with progressive external ophthalmoplegia phenotype (PEO) associated with POLG mutation effectively treated with erenumab, in the absence of side effects. Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) or against its receptor are innovative and specific therapies for migraine prophylaxis. This class of drugs is particularly suitable for subjects, such as those suffering from genetically determined mitochondrial dysfunction, in which pharmacological management can represent a challenge due to the nature of these neurogenetic disorders and/or the frequently associated comorbidities.
    MeSH term(s) Humans ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Antibodies, Monoclonal, Humanized/therapeutic use ; Mitochondrial Diseases/drug therapy ; Mitochondrial Diseases/genetics
    Chemical Substances Calcitonin Gene-Related Peptide Receptor Antagonists ; erenumab (I5I8VB78VT) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2022-09-13
    Publishing country Italy
    Document type Review ; Case Reports ; Journal Article
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-022-06391-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Microvascular involvement in migraine: an optical coherence tomography angiography study.

    Romozzi, Marina / Cuffaro, Giovanni / Rollo, Eleonora / Mattei, Roberta / Marcelli, Sofia / Rizzo, Stanislao / Calabresi, Paolo / Servidei, Serenella / Savino, Gustavo / Vollono, Catello

    Journal of neurology

    2023  Volume 270, Issue 8, Page(s) 4024–4030

    Abstract: Objective: The aim of this study was to evaluate the microvasculature of the macula and the optic nerve in patients affected by migraine with aura (MA) and without aura (MO) by optical coherence tomography angiography (OCTA), comparing the findings with ...

    Abstract Objective: The aim of this study was to evaluate the microvasculature of the macula and the optic nerve in patients affected by migraine with aura (MA) and without aura (MO) by optical coherence tomography angiography (OCTA), comparing the findings with healthy controls (HC).
    Methods: We collected data from ocular and orthotic examinations, including eye motility, intraocular pressure measurement, best-corrected visual acuity (BCVA) measurement, objective refraction measurement, fundus examination, macular and optic disk OCTA examination. All subjects were imaged with solix fullrange OCT. The following OCTA parameters were recorded: macular vessel density (VD), inside disc VD, peripapillary VD, disc whole image VD, fovea choriocapillaris VD, fovea VD, parafovea VD, peripapillary thickness, fovea thickness, parafovea thickness, macular full retinal thickness, and foveal avascular zone (FAZ) parameters. Clinical and demographical data about migraine patients were collected by a neurologist.
    Results: We included 56 eyes from 28 patients with a diagnosis of MO, 32 eyes from 16 patients with a diagnosis of MA, and 32 eyes from 16 HC subjects. The FAZ area was 0.230 ± 0.099 mm
    Conclusion: An impairment of retinal microcirculation can be detected in patients with MA, as demonstrated by the enlargement of FAZ. Moreover, the study of choroid circulation may reveal microvascular damage in patients with migraine with aura. OCTA is a useful non-invasive screening tool for the detection of microcirculatory disturbance in patients with migraine.
    MeSH term(s) Humans ; Fluorescein Angiography/methods ; Retinal Vessels/diagnostic imaging ; Migraine with Aura ; Tomography, Optical Coherence/methods ; Microcirculation
    Language English
    Publishing date 2023-05-08
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 187050-6
    ISSN 1432-1459 ; 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    ISSN (online) 1432-1459
    ISSN 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    DOI 10.1007/s00415-023-11697-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB

    Giuseppe Tringali / Catello Vollono / Paolo Calabresi / Pierluigi Navarra

    The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-

    2020  Volume 2

    Abstract: Abstract The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological ... ...

    Abstract Abstract The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we have measured the circulating levels of CGRP in 7 patients with high-frequency episodic migraine receiving the anti-CGRP receptor mAb erenumab for at least 6 months, to test the hypothesis that long-term blockade of CGRP receptors induces an increase in systemic CGRP levels via a classical up-regulation mechanism. Plasma CGRP levels were measured by a validated radioimmunoassay at baseline, and after 1 and 6 months of treatment with erenumab, 70 mg given sc every 4 weeks. We found (data expressed as the means ± SD): 38.34 ± 30.74 pg CGRP/ml of plasma at baseline, 38.19 ± 29.23 pg/ml after 1 month and 53.89 ± 28.03 pg/ml after 6 months of treatment. Thus, the average increase in plasma CGRP levels after 6 months of treatment was about + 40% compared to both baseline and 1-month treatments; such difference was not statistically significant because of high SD values in all groups. These preliminary findings need to be confirmed in larger, sufficiently powered experiments.
    Keywords CGRP ; CGRP receptor ; Monoclonal antibodies ; Erenumab ; Migraine ; Medicine ; R
    Subject code 616
    Language English
    Publishing date 2020-10-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article: Association of Obstructive Sleep Apnea and Atrial Fibrillation in Acute Ischemic Stroke: A Cross-Sectional Study.

    Brunetti, Valerio / Testani, Elisa / Losurdo, Anna / Vollono, Catello / Broccolini, Aldobrando / Di Iorio, Riccardo / Frisullo, Giovanni / Pilato, Fabio / Profice, Paolo / Marotta, Jessica / Rollo, Eleonora / Scala, Irene / Calabresi, Paolo / Della Marca, Giacomo

    Journal of personalized medicine

    2023  Volume 13, Issue 3

    Abstract: ... ...

    Abstract Background
    Language English
    Publishing date 2023-03-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662248-8
    ISSN 2075-4426
    ISSN 2075-4426
    DOI 10.3390/jpm13030527
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Epilepsy management in mitochondrial diseases.

    Primiano, Guido / Vollono, Catello / Dono, Fedele / Servidei, Serenella

    Epilepsy research

    2018  Volume 147, Page(s) 108

    MeSH term(s) Anticonvulsants/therapeutic use ; Cohort Studies ; Disease Management ; Epilepsy/etiology ; Epilepsy/therapy ; Female ; Humans ; Male ; Mitochondrial Diseases/complications
    Chemical Substances Anticonvulsants
    Language English
    Publishing date 2018-09-25
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 632939-1
    ISSN 1872-6844 ; 0920-1211
    ISSN (online) 1872-6844
    ISSN 0920-1211
    DOI 10.1016/j.eplepsyres.2018.09.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top